AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10740332 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of 17beta‐oestradiol continuously combined with 1 mg of norethisterone acetate (E2+NETA)
Number of subjects: 200
Study 10740332 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of piperazine oestrone sulphate plus 0.7 mg of norethisterone (highEP)
Number of subjects: 200
Study 10740332 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg of piperazine oestrone sulphate plus 0.35 mg of norethisterone (lowEP)
Number of subjects: 200
Study 10740332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9361397 — intervention group
Group type: EXPERIMENTAL
Intervention: Transabdominal ultrasound
Number of subjects: 66
Study 9361397 — intervention group
Group type: COMPARATOR
Intervention: Vaginal ultrasound
Number of subjects: 66
Study 9361397 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovaginal probe
Number of subjects: 66
Study 9361397 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal sonography
Number of subjects: 66
Study 8476831 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic progestogen in addition to conventional therapy
Number of subjects: 257
Study 8476831 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 257
Study 3084316 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) with chlorpromazine (CPZ)
Number of subjects: 30
Study 3084316 — intervention group
Group type: COMPARATOR
Intervention: Lithium with chlorpromazine (CPZ)
Number of subjects: 30
Study 29122372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet 30mcg (SST 30mcg) - single-dose cohort
Number of subjects: 76
Study 29122372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet 30mcg (SST 30mcg) - multiple-dose cohort
Number of subjects: 76
Study 29122372 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil sublingual tablet 30mcg (SST 30mcg) - combined cohorts
Number of subjects: 76
Study 28460717 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld, pocket‐sized ultrasound for diagnosing distal radius fractures
Number of subjects: 23
Study 28460717 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld, pocket‐sized ultrasound for assessing reduction adequacy
Number of subjects: 23
Study 28460717 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability between musculoskeletal radiologist and hand surgeon
Number of subjects: 23
Study 28460717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrarater reliability
Number of subjects: 23
Study 28460717 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard radiographic and ultrasonographic examination)
Number of subjects: 23
Study 25393566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (n=26)
Number of subjects: 52
Study 25393566 — intervention group
Group type: COMPARATOR
Intervention: Supine position (n=26)
Number of subjects: 52
Study 23429918 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg three times daily
Number of subjects: 63
Study 23429918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 21789702 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (50 mg)
Number of subjects: 361
Study 21789702 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg)
Number of subjects: 361
Study 21789702 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (1.25 mg)
Number of subjects: 361
Study 18443390 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only cognitive behavioral therapy (CBT)
Number of subjects: 56
Study 18443390 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child cognitive behavioral therapy (CBT)
Number of subjects: 56
Study 17156624 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 sympathectomy (Group B, n = 131)
Number of subjects: 398
Study 17156624 — intervention group
Group type: EXPERIMENTAL
Intervention: T3-4 sympathectomy (Group C, n = 60)
Number of subjects: 398
Study 17156624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (Group B + C)
Number of subjects: 398
Study 17156624 — intervention group
Group type: COMPARATOR
Intervention: T2-4 sympathectomy (Group A, n = 207)
Number of subjects: 398
Study 12942707 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased colchicine dose in 26 randomly chosen patients with no attacks in the last year.
Number of subjects: 183
Study 12942707 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (baseline A‐SAA levels during attack-free period).
Number of subjects: 183
Study 12942707 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (comparison of A‐SAA levels based on genetic mutations).
Number of subjects: 183
Study 10765123 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m(2)) followed by 5‐FU (600 mg/m(2)) weekly for 3 weeks of every 4
Number of subjects: 36
Study 10765123 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 36
Study 9375868 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographs of the feet at baseline and 12 months
Number of subjects: 284
Study 1609379 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium intake
Number of subjects: 17
Study 1609379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake
Number of subjects: 17
Study 1609379 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake
Number of subjects: 17
Study 3897559 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of praziquantel 40 mg/kg bodyweight
Number of subjects: 0
Study 3897559 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dose of praziquantel 2 X 20 mg/kg given 4‐6 h apart
Number of subjects: 0
Study 31752647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) + Individual Placement and Support (IPS) (n = 28)
Number of subjects: 57
Study 31752647 — intervention group
Group type: COMPARATOR
Intervention: IPS alone (n = 29)
Number of subjects: 57
Study 31752647 — intervention group
Group type: EXPERIMENTAL
Intervention: CR + IPS
Number of subjects: 57
Study 31176295 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment
Number of subjects: 50
Study 31176295 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 50
Study 31176295 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment resting-state functional connectivity (rsFC)
Number of subjects: 50
Study 29223508 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/Formoterol combination via dry powder inhalers
Number of subjects: 0
Study 29223508 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled FOR
Number of subjects: 0
Study 29223508 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled BUD
Number of subjects: 0
Study 29223508 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential covariates
Number of subjects: 0
Study 26847320 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot active assisted therapy (RT)
Number of subjects: 17
Study 26847320 — intervention group
Group type: COMPARATOR
Intervention: Classical occupational therapy (OT)
Number of subjects: 17
Study 23754782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (MOVE/me Muevo)
Number of subjects: 541
Study 23754782 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 541
Study 23722990 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine-augmented exposure and response prevention (ERP + DCS)
Number of subjects: 17
Study 23722990 — intervention group
Group type: COMPARATOR
Intervention: Placebo-augmented exposure and response prevention (ERP + PBO)
Number of subjects: 17
Study 20668807 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum women with PPD
Number of subjects: 440
Study 17517442 — intervention group
Group type: EXPERIMENTAL
Intervention: Health counseling, guidance, and adjustment education (1 guidance and counseling session + 4 sessions within 12 months)
Number of subjects: 117
Study 16880426 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet intervention
Number of subjects: 0
Study 12880874 — intervention group
Group type: EXPERIMENTAL
Intervention: Print program (8-week, stage-targeted)
Number of subjects: 655
Study 12880874 — intervention group
Group type: EXPERIMENTAL
Intervention: Web program (8-week, stage-targeted)
Number of subjects: 655
Study 10963640 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 75 (11 cycles of fluorouracil 500 mg/m(2), epirubicin 75 mg/m(2), and cyclophosphamide 500 mg/m(2) every 21 days)
Number of subjects: 417
Study 10963640 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 100 (four cycles of epirubicin 100 mg/m(2) then eight cycles of epirubicin 50 mg/m(2))
Number of subjects: 417
Study 10963640 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 100 followed by retreatment at disease progression
Number of subjects: 417
Study 10963640 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 100 (four cycles)
Number of subjects: 417
Study 10963640 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 100 (arm B)
Number of subjects: 417
Study 10963640 — intervention group
Group type: COMPARATOR
Intervention: FEC 75 (arm A)
Number of subjects: 417
Study 10963640 — intervention group
Group type: COMPARATOR
Intervention: FEC 100 followed by retreatment at disease progression (arm C)
Number of subjects: 417
Study 7534423 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride at 12 mg/day
Number of subjects: 32
Study 7534423 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride at 2 mg/day
Number of subjects: 32
Study 7534423 — intervention group
Group type: EXPERIMENTAL
Intervention: Raclopride at 6 mg/day
Number of subjects: 32
Study 7534423 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol at 15 mg/day
Number of subjects: 32
Study 3362801 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational videotapes
Number of subjects: 603
Study 3362801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (brief individual treatment)
Number of subjects: 603
Study 3362801 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 603
Study 3362801 — intervention group
Group type: COMPARATOR
Intervention: Invited but did not attend (control group)
Number of subjects: 603
Study 31773749 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective caries removal (SR)
Number of subjects: 255
Study 31773749 — intervention group
Group type: COMPARATOR
Intervention: Non-selective removal to hard dentine
Number of subjects: 255
Study 30414528 — intervention group
Group type: EXPERIMENTAL
Intervention: nal-IRI+5-FU/LV
Number of subjects: 66
Study 30414528 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 66
Study 28259039 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward step training (FT)
Number of subjects: 54
Study 28259039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral plus forward step training (FLT)
Number of subjects: 54
Study 28259039 — intervention group
Group type: COMPARATOR
Intervention: No training (NT)
Number of subjects: 54
Study 27235824 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic priming with healthy body image words (e.g., 'slim', 'fit')
Number of subjects: 161
Study 27235824 — intervention group
Group type: COMPARATOR
Intervention: Neutral prime
Number of subjects: 161
Study 23510061 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (AD)
Number of subjects: 241
Study 23510061 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail (DM)
Number of subjects: 241
Study 23510061 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 241
Study 21086245 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown visit
Number of subjects: 100
Study 21086245 — intervention group
Group type: COMPARATOR
Intervention: No-visit control
Number of subjects: 100
Study 20002421 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth education program for expectant fathers
Number of subjects: 87
Study 20002421 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 17307102 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4724
Study 17307102 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4724
Study 15489085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (antiplatelet plus moderate-intensity anticoagulation)
Number of subjects: 1209
Study 15489085 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 1209
Study 11181493 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan at a dose of 16 mg/kg
Number of subjects: 0
Study 11181493 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alpha GST levels
Number of subjects: 0
Study 11181493 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic GST activity
Number of subjects: 0
Study 11181493 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma alpha GST concentrations
Number of subjects: 0
Study 9692701 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Gaviscon (20 ml dose)
Number of subjects: 12
Study 9692701 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control group)
Number of subjects: 12
Study 8558412 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and weight training (n = 22)
Number of subjects: 59
Study 8558412 — intervention group
Group type: COMPARATOR
Intervention: Ordinary aerobic training alone (n = 19)
Number of subjects: 59
Study 8558412 — intervention group
Group type: COMPARATOR
Intervention: No physical training (n = 18)
Number of subjects: 59
Study 2196536 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 10 mg orally
Number of subjects: 75
Study 2196536 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg plus codeine 60 mg orally
Number of subjects: 75
Study 2196536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 273321 — intervention group
Group type: EXPERIMENTAL
Intervention: Silka toothpaste
Number of subjects: 0
Study 273321 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste without periodontal‐prophylactic adjuncts
Number of subjects: 0
Study 30866143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryocystography (DCG)
Number of subjects: 165
Study 30866143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryoscintigraphy (DSG)
Number of subjects: 165
Study 29229659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirroring intervention using the Smokerface app for 45 minutes, delivered by medical students.
Number of subjects: 735
Study 29229659 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 735
Study 26053411 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvest (EVH)
Number of subjects: 126
Study 26053411 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvest (OVH)
Number of subjects: 126
Study 23906899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 43
Study 23906899 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 43
Study 21751285 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 34
Study 21751285 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) volumetry
Number of subjects: 34
Study 21751285 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tumor volume reduction rate
Number of subjects: 34
Study 21751285 — intervention group
Group type: COMPARATOR
Intervention: Tumor regression grade (TRG)
Number of subjects: 34
Study 19537357 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera) three times daily prior to meals
Number of subjects: 40
Study 19537357 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin glargine (Lantus) once daily
Number of subjects: 40
Study 16719028 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented intervention (practice of functional, unilateral and bilateral tasks)
Number of subjects: 91
Study 16719028 — intervention group
Group type: COMPARATOR
Intervention: Walking tasks (control intervention)
Number of subjects: 91
Study 15317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 5 mg
Number of subjects: 2
Study 15317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 10 mg
Number of subjects: 2
Study 15317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 20 mg
Number of subjects: 2
Study 15317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 30 mg
Number of subjects: 2
Study 15317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate 100 mg
Number of subjects: 2
Study 15317830 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate (various doses)
Number of subjects: 2
Study 10945312 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.6 mg
Number of subjects: 32
Study 10945312 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.9 mg
Number of subjects: 32
Study 10945312 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine 1.2 mg
Number of subjects: 32
Study 10945312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9243349 — intervention group
Group type: COMPARATOR
Intervention: 9-cis-retinoic acid (5 mg, 15 mg, 40 mg, 80 mg, 150 mg)
Number of subjects: 40
Study 9243349 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-cis-retinoic acid (various doses)
Number of subjects: 40
Study 9243349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7954483 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide (300 mg daily)
Number of subjects: 80
Study 7954483 — intervention group
Group type: COMPARATOR
Intervention: maprotiline (75 mg daily)
Number of subjects: 80
Study 3118861 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms capsule)
Number of subjects: 164
Study 3118861 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg tablet)
Number of subjects: 164
Study 29669531 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-I
Number of subjects: 1981
Study 25490158 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Support in Physical Activity Consultations Observational Tool (ISPACOT)
Number of subjects: 42
Study 25490158 — intervention group
Group type: COMPARATOR
Intervention: Low interpersonally supportive features consultations
Number of subjects: 42
Study 25490158 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained advisors in Self-determination Theory (SDT) principles
Number of subjects: 42
Study 24238714 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 297
Study 22995653 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg, once daily) plus prednisone (5 mg, orally twice daily)
Number of subjects: 1195
Study 22995653 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prednisone (5 mg, orally twice daily)
Number of subjects: 1195
Study 21105368 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with visible and near infrared light (480‐3400 nm, 95 % polarization, 40 mW/cm2, 12 J/cm2) for 7 days
Number of subjects: 0
Study 21105368 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy with visible and near infrared light
Number of subjects: 0
Study 18953051 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC conditioned supernatants (BMC-SN)
Number of subjects: 15
Study 18953051 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL conditioned supernatants (PBL-SN)
Number of subjects: 15
Study 18953051 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC-SN and PBL-SN in combination
Number of subjects: 15
Study 18953051 — intervention group
Group type: EXPERIMENTAL
Intervention: BMCs and PBLs
Number of subjects: 15
Study 15683890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etching
Number of subjects: 50
Study 15683890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting prior to acid etching
Number of subjects: 50
Study 15683890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual bonding
Number of subjects: 50
Study 15683890 — intervention group
Group type: COMPARATOR
Intervention: Buccal bonding
Number of subjects: 50
Study 12841540 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium gluconolactate administration (1 g)
Number of subjects: 102
Study 12841540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parameters of Product P and Ratio R
Number of subjects: 102
Study 10391666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg twice a day for 7 days)
Number of subjects: 18
Study 10391666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8853756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily (L15)
Number of subjects: 235
Study 8853756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily (L30)
Number of subjects: 235
Study 8853756 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg b.d. (R600)
Number of subjects: 235
Study 1737544 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (11.9 mg)
Number of subjects: 21
Study 1737544 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (8.4 mg)
Number of subjects: 21
Study 1737544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Glipizide and Glyburide)
Number of subjects: 21
Study 1737544 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 21
Study 6336862 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gentamicin (80 mg) and clindamycin (600 mg) administered intravenously, three doses daily for 2 days.
Number of subjects: 107
Study 6336862 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of gentamicin (80 mg) and metronidazole (500 mg) administered intravenously, three doses daily for 2 days.
Number of subjects: 107
Study 6336862 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a barium enema for radiologic assessment.
Number of subjects: 107
Study 6336862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (gentamicin with clindamycin and gentamicin with metronidazole).
Number of subjects: 107